Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL

Cervarix

Subjects will receive three doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.

Trial Locations (1)

GSK Investigational Site, Hong Kong